Aclaris Therapeutics Gross Profit Over Time
| ACRS Stock | USD 3.82 0.19 5.23% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aclaris Therapeutics Performance and Aclaris Therapeutics Correlation. Aclaris |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclaris Therapeutics. If investors know Aclaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclaris Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.381 | Quarterly Revenue Growth (0.53) | Return On Assets (0.19) | Return On Equity (0.26) |
The market value of Aclaris Therapeutics is measured differently than its book value, which is the value of Aclaris that is recorded on the company's balance sheet. Investors also form their own opinion of Aclaris Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aclaris Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclaris Therapeutics' market value can be influenced by many factors that don't directly affect Aclaris Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclaris Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclaris Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclaris Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare Aclaris Therapeutics and related stocks such as Neogen, Qiagen NV, and Olink Holding AB Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEOG | 2.1 M | 92.4 M | 109.5 M | 122.6 M | 139.7 M | 153.1 M | 172 M | 190.3 M | 191.9 M | 196.3 M | 215.1 M | 243 M | 406 M | 463.9 M | 487.1 M |
| QGEN | 29.3 M | 749.8 M | 824 M | 815.5 M | 864.9 M | 826.4 M | 844.7 M | 922.6 M | 1 B | 1 B | 1.2 B | 1.5 B | 1.4 B | 1.2 B | 664 M |
| SHC | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 395.4 M | 443.6 M | 518.7 M | 557 M | 577.2 M | 522.3 M |
| RDNT | 45.3 M | 142 M | 104.2 M | 104.3 M | 114.9 M | 101.3 M | 108.7 M | 119.8 M | 107.6 M | 154.5 M | 105.9 M | 191.8 M | 165.7 M | 221.4 M | 232.5 M |
| MYGN | 8.2 M | 355.4 M | 431.3 M | 533.5 M | 669 M | 575.7 M | 596.5 M | 600.2 M | 595.4 M | 650.1 M | 378.8 M | 493 M | 476.4 M | 517 M | 327.5 M |
| BDSX | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 18.5 M | 23.6 M | 24 M | 24.1 M | 36.1 M | 26.1 M |
| CSTL | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 8.8 M | 17.5 M | 44.6 M | 53 M | 78.3 M | 105 M | 174.8 M | 183.5 M |
| PRE | 127.3 M | 1.4 B | 1.4 B | 860.4 M | 1.4 B | 668.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 26.3 M | 106.1 M | 131.6 M | 8.8 M | 8.4 M |
| IQV | 1.1 B | 1.1 B | 1.2 B | 1.3 B | 1.5 B | 1.6 B | 2.1 B | 3.4 B | 3.7 B | 3.8 B | 3.9 B | 4.6 B | 5 B | 5.2 B | 3.1 B |
| MEDP | 124.5 M | 124.5 M | 124.5 M | 124.5 M | 133.7 M | 156.4 M | 172.1 M | 174.7 M | 215.5 M | 245.7 M | 278.7 M | 328.2 M | 432.4 M | 524.5 M | 278.6 M |
| ICLR | 42.1 M | 333.8 M | 396.9 M | 490.6 M | 600.1 M | 666 M | 705.2 M | 727 M | 769.5 M | 831.7 M | 808 M | 1.5 B | 2.2 B | 2.4 B | 2.5 B |
Aclaris Therapeutics and related stocks such as Neogen, Qiagen NV, and Olink Holding AB Gross Profit description
Gross profit is a required income statement account that reflects total revenue of Aclaris Therapeutics minus its cost of goods sold. It is profit before Aclaris Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| Aclaris Therapeutics | ACRS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 3.82
Additional Tools for Aclaris Stock Analysis
When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.